Blumenfeld et al. “Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.” Pain Ther (2021). doi:10.1007/s40122-021-00264-x
This high attack frequency can seriously impair unfortunately, the disease’s complexity makes treatment difficult, two approved preventive treatments for and antibody-based inhibitors of calcitonin gene-related peptide, or cgrp. onabotulinumtoxina is administered to muscles surrounding the head and neck and near sensory nerves.
At the nerve terminal, it disrupts pain signals by reducing synaptic and by inhibiting insertion of pain-sensitive ion channels. on cgrp receptors or the cgrp ligand preclinical data suggest that the two types of agents inhibit onabotulinumtoxina primarily inhibits c-fibers, the different mechanisms of action suggest that adding cgrp
Inhibitors to onabotulinumtoxina treatment may produce additive patients who don’t achieve sufficient relief from clinical reports have indicated benefits of this combination therapy, but no randomized controlled trials have been performed. a retrospective longitudinal chart review recently assessed the effects of onabotulinumtoxina treatment
And subsequent onabotulinumtoxina among 257 patients at and outcome measures were assessed for up to 1 onabotulinumtoxina alone effectively decreased inhibitor significantly reduced the number of combined treatment also resulted in significantly and clinically meaningful improvements in migraine-related disability the combination
Treatment regimen was well tolerated, with no new safety signals reported. approximately one-quarter of patients discontinued lack of insurance reimbursement was the additional studies, including controlled trials, are warranted overall, however, this real-world study adding cgrp inhibitors to onabotulinumtoxina provides clinically
Meaningful benefits for patients with chronic migraine.
Transcribed from video
Real-world data suggests that adding CGRP inhibitors to onabotulinumtoxinA adds efficacy By Research Square